China is the world's largest producer and consumer of
pork with the output volume of pork accounting for nearly 50% of the
total. The output volume of pork was 54.93 million tons in China in
2013, up by 2.8% YOY. The livestock volume of pigs was 474.11
million, down by 0.4% YOY while the stock volume of fattened pigs was
715.57 million, up by 2.5% YOY.
The PRRS broke out in southern China and spread rapidly nationwide
after summer in 2006, which lead to increases in mortality rate of
piglets and pork prices and significant decrease in output volume of
pork. In May 2007, the Ministry of Agriculture of China approved the
production of highlypathogenic porcine reproductive and respiratory
syndrome inactivated vaccine (NVDCJXA1) in six manufacturers of
biological products. Porcine reproductive and respiratory syndrome
(PRRS) remains one of the key compulsory immunity diseases in China.
According to National Compulsory Immunization Plan of Animal Epidemic
Diseases in 2014 issued by Ministry of Agriculture of China, the
government conducts compulsory immunizations against 4 diseases,
including highlypathogenic PRRS. The government is responsible for
the expenses. Currently highly pathogenic PRRS vaccines are purchased
by the government through invitation for bidding in China.
The market competition is intensive in the PRRS vaccine industry in
China. There are 26 manufacturers of PRRS vaccines in China,
including Dahuanong, Xinjiang Tecon Animal Husbandry BioTechnology
Co., Ltd., Qingdao Yebio Bioengineering Co., Ltd. and Inner Mongolia
Jinyu Group Stock Company. In terms of the direct sales of highend
vaccines, the PRRS vaccines of Zoetis went to the market in Guangzhou
at the end of August 2013 after Boehringer. These foreignfunded
vaccine brands occupy the market shares using the brand advantages,
which intensify the market competition. ...